Skip to main content
Medical information Clinical review pending

Genetic Testing

ALG11 Gene Congenital Disorder of Glycosylation Type Ip Genetic Test

Genetic test to identify mutations in the ALG11 gene, associated with Congenital Disorder of Glycosylation Type Ip, a metabolic disorder. Uses Next-Generation Sequencing (NGS) technology.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube), Extracted DNA, or One drop of blood on an FTA card.
Results
Confirm with the laboratory before booking.
Preparation
A clinical history must be provided. Genetic counseling is recommended to establish a family pedigree chart, especially if other family members are affected by congenital disorders of glycosylation.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the ALG11 Gene Congenital Disorder of Glycosylation Type Ip Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Suspected Congenital Disorder of Glycosylation (CDG) Type Ip.
  • ✓Presence of symptoms like developmental delays or neurological issues.
  • ✓Family history of CDG or related metabolic disorders.
  • ✓Unexplained metabolic abnormalities.
  • ✓Confirmation of diagnosis after initial screening tests.
02

In plain language

What this test helps you understand

This test helps identify specific genetic mutations in the ALG11 gene associated with Congenital Disorder of Glycosylation Type Ip. This information can aid in confirming a diagnosis, understanding the underlying cause of symptoms, guiding treatment decisions, and providing genetic counseling for affected individuals and their families.
The ALG11 Gene Congenital Disorder of Glycosylation Type Ip NGS Genetic DNA Test is a specialized genetic analysis designed to detect mutations within the ALG11 gene. These mutations are linked to Congenital Disorders of Glycosylation (CDG), specifically Type Ip, which are metabolic conditions affecting the body's ability to process sugars. This test is important for diagnosing these complex disorders and guiding patient management.

This test utilizes advanced Next-Generation Sequencing (NGS) technology to examine the ALG11 gene for variations that may cause disease. Identifying these genetic changes can help healthcare providers understand the cause of a patient's symptoms and develop appropriate treatment strategies.

This test is recommended for individuals presenting with symptoms suggestive of a metabolic disorder, those with a family history of CDG, or patients where previous testing suggests a glycosylation issue.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationA clinical history must be provided. Genetic counseling is recommended to establish a family pedigree chart, especially if other family members are affected by congenital disorders of glycosylation.
SampleBlood sample (EDTA tube), Extracted DNA, or One drop of blood on an FTA card.
MethodologyNext-Generation Sequencing (NGS) of the ALG11 gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically analyzes the ALG11 gene. It may not detect mutations in other genes associated with CDG or other metabolic disorders. A negative result does not completely rule out a diagnosis. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

It is a rare metabolic disorder caused by mutations in the ALG11 gene, affecting the body's ability to attach sugars to proteins (glycosylation).
Individuals with symptoms suggestive of CDG Type Ip, a family history of the disorder, or unexplained metabolic issues may be recommended for this test.
A blood sample, extracted DNA, or a single drop of blood on an FTA card can be used. Home sample collection may be available.
Turnaround time varies. Please confirm the current estimated time with the laboratory before booking.
A positive result indicates the presence of a mutation in the ALG11 gene associated with CDG Type Ip. Further consultation with a doctor is needed to understand the implications.
Yes, genetic counseling is highly recommended before and after testing to understand the test, its implications, and family risks.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp